Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Forest Gains Lexapro Approval in Adolescents | Contract Pharma

What are you searching for?

Sign in

Forest Gains Lexapro Approval in Adolescents

Forest Laboratories received approval from the FDA for its sNDA for Lexapro for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, ages 12 to 17.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Forest Laboratories received approval from the FDA for its sNDA for Lexapro for the acute and maintenance treatment of Major Depressive Disorder (MDD) in adolescents, ages 12 to 17. Lexapro is the second antidepressant to be approved for the treatment of MDD in adolescents.

The approval was supported by two placebo-controlled studies, one conducted in adolescent patients taking Lexapro and one conducted in children and adolescents taking citalopram. In an eight-week study that compared Lexapro 10-20 mg/day to placebo, patients showed statistically significant improvement from baseline, compared to placebo, on the Children’s Depression Rating Scale-Revised (CDRS-R).

“Major depressive disorder in adolescents is a debilitating, but treatable illness,” said Howard Solomon, chairman and chief executive officer of Forest. “We have long believed that Lexapro would be of benefit for the treatment of depression in adolescents and that is why we undertook the several studies described in the package insert. We are enormously gratified that Lexapro will be available for depressed adolescents who so much require the benefits which Lexapro has made available for depressed adults for the past seven years.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters